Acasti Pharma Stock Price Prediction

ACST Stock  USD 3.19  0.22  7.41%   
At this time, the relative strength index (RSI) of Acasti Pharma's share price is approaching 34. This suggests that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Acasti Pharma, making its price go up or down.

Oversold Vs Overbought

34

 
Oversold
 
Overbought
The successful prediction of Acasti Pharma's future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Acasti Pharma, which may create opportunities for some arbitrage if properly timed.
Using Acasti Pharma hype-based prediction, you can estimate the value of Acasti Pharma from the perspective of Acasti Pharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Acasti Pharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Acasti because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Acasti Pharma after-hype prediction price

    
  USD 3.19  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Acasti Pharma Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Acasti Stock please use our How to Invest in Acasti Pharma guide.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Acasti Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
0.112.294.90
Details
Naive
Forecast
LowNextHigh
0.633.245.85
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.552.833.12
Details

Acasti Pharma After-Hype Price Prediction Density Analysis

As far as predicting the price of Acasti Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Acasti Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Acasti Pharma, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Acasti Pharma Estimiated After-Hype Price Volatility

In the context of predicting Acasti Pharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Acasti Pharma's historical news coverage. Acasti Pharma's after-hype downside and upside margins for the prediction period are 0.58 and 5.80, respectively. We have considered Acasti Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
3.19
3.19
After-hype Price
5.80
Upside
Acasti Pharma is unstable at this time. Analysis and calculation of next after-hype price of Acasti Pharma is based on 3 months time horizon.

Acasti Pharma Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Acasti Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Acasti Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Acasti Pharma, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.11 
2.64
 0.00  
 0.00  
0 Events / Month
0 Events / Month
In 5 to 10 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
3.19
3.19
0.00 
0.00  
Notes

Acasti Pharma Hype Timeline

Acasti Pharma is presently traded for 3.19. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Acasti is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is projected to be very small, whereas the daily expected return is presently at -0.11%. %. The volatility of related hype on Acasti Pharma is about 0.0%, with the expected price after the next announcement by competition of 3.19. About 16.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.49. Some equities with similar Price to Book (P/B) outperform the market in the long run. Acasti Pharma recorded a loss per share of 5.68. The entity had not issued any dividends in recent years. The firm had 1:6 split on the 10th of July 2023. Given the investment horizon of 90 days the next projected press release will be in 5 to 10 days.
Check out Acasti Pharma Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Acasti Stock please use our How to Invest in Acasti Pharma guide.

Acasti Pharma Related Hype Analysis

Having access to credible news sources related to Acasti Pharma's direct competition is more important than ever and may enhance your ability to predict Acasti Pharma's future price movements. Getting to know how Acasti Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Acasti Pharma may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
TNXPTonix Pharmaceuticals Holding 0.00 0 per month 0.00 (0.20) 6.25 (10.53) 48.48 
JAGXJaguar Animal Health 0.00 0 per month 10.45  0.04  28.89 (15.41) 84.82 
DFFNDiffusion Pharmaceuticals 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
IBIOIbio Inc 0.00 0 per month 5.60  0.11  9.39 (14.63) 209.66 
ARDSAridis Pharmaceuticals 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
AKTXAkari Therapeutics PLC 0.00 0 per month 5.45  0.04  13.10 (7.48) 33.84 
ADTXAditxt Inc 0.00 0 per month 0.00 (0.21) 6.11 (8.31) 23.14 
ABVCABVC Biopharma 0.00 0 per month 0.00 (0.08) 9.17 (8.93) 40.52 
PULMPulmatrix 0.00 0 per month 2.93  0.04  6.91 (5.10) 17.39 
ONTXOnconova Therapeutics 0.00 0 per month 0.00  0.24  697.00 (7.78) 697.50 
CBIOCatalyst Biosciences 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
BPTHBio Path Holdings 0.00 0 per month 0.00 (0.06) 10.70 (13.30) 78.81 
MBRXMoleculin Biotech 0.00 0 per month 0.00 (0.17) 7.95 (10.86) 30.91 
ADXSAyala Pharmaceuticals 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
GOVXGeoVax Labs 0.00 0 per month 0.00 (0.08) 7.98 (6.56) 25.77 
OCGNOcugen Inc 0.00 0 per month 4.97  0.14  15.29 (8.33) 32.78 

Acasti Pharma Additional Predictive Modules

Most predictive techniques to examine Acasti price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Acasti using various technical indicators. When you analyze Acasti charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Acasti Pharma Predictive Indicators

The successful prediction of Acasti Pharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Acasti Pharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Acasti Pharma based on analysis of Acasti Pharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Acasti Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Acasti Pharma's related companies.

Story Coverage note for Acasti Pharma

The number of cover stories for Acasti Pharma depends on current market conditions and Acasti Pharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Acasti Pharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Acasti Pharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Acasti Pharma Short Properties

Acasti Pharma's future price predictability will typically decrease when Acasti Pharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Acasti Pharma often depends not only on the future outlook of the potential Acasti Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Acasti Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding7.4 M
Cash And Short Term Investments27.9 M

Additional Tools for Acasti Stock Analysis

When running Acasti Pharma's price analysis, check to measure Acasti Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acasti Pharma is operating at the current time. Most of Acasti Pharma's value examination focuses on studying past and present price action to predict the probability of Acasti Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acasti Pharma's price. Additionally, you may evaluate how the addition of Acasti Pharma to your portfolios can decrease your overall portfolio volatility.